Search Results

There are 11597 results for: content related to: Use of Vasculature-disrupting Agents in Non-Oncology Indications

  1. You have free access to this content
    An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate

    British Journal of Pharmacology

    Volume 171, Issue 21, November 2014, Pages: 4902–4913, L J Williams, D Mukherjee, M Fisher, C C Reyes-Aldasoro, S Akerman, C Kanthou and G M Tozer

    Version of Record online : 24 OCT 2014, DOI: 10.1111/bph.12817

  2. MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent

    PROTEOMICS

    Volume 14, Issue 7-8, April 2014, Pages: 890–903, Laura M. Cole, Joanne E. Bluff, Vikki A. Carolan, Martyn N. Paley, Gillian M. Tozer and Malcolm R. Clench

    Version of Record online : 1 APR 2014, DOI: 10.1002/pmic.201300429

  3. You have free access to this content
    Disrupting established tumor blood vessels

    Cancer

    Volume 116, Issue 8, 15 April 2010, Pages: 1859–1871, Mark J. McKeage and Bruce C. Baguley

    Version of Record online : 17 FEB 2010, DOI: 10.1002/cncr.24975

  4. Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents

    Vascular-Targeted Therapies in Oncology

    Dietmar W. Siemann, Pages: 95–121, 2006

    Published Online : 31 MAY 2006, DOI: 10.1002/0470035439.ch6

  5. You have free access to this content
    Anti-vascular endothelial growth factor for myopic choroidal neovascularization

    Clinical & Experimental Ophthalmology

    Volume 40, Issue 1, January/February 2012, Pages: e98–e110, Danny S Ng, Alvin KH Kwok and Clement W Chan

    Version of Record online : 5 FEB 2012, DOI: 10.1111/j.1442-9071.2011.02684.x

  6. You have free access to this content
    Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

    International Journal of Experimental Pathology

    Volume 90, Issue 3, June 2009, Pages: 284–294, Chryso Kanthou and Gillian M. Tozer

    Version of Record online : 11 MAY 2009, DOI: 10.1111/j.1365-2613.2009.00651.x

  7. Colchicine site inhibitors of microtubule integrity as vascular disrupting agents

    Drug Development Research

    Volume 69, Issue 6, September 2008, Pages: 352–358, Ray M. Lee and David A. Gewirtz

    Version of Record online : 9 DEC 2008, DOI: 10.1002/ddr.20267

  8. Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models

    Vascular-Targeted Therapies in Oncology

    Mumtaz V. Rojiani, Amyn M. Rojiani, Pages: 81–94, 2006

    Published Online : 31 MAY 2006, DOI: 10.1002/0470035439.ch5

  9. Retina, Vitreous

    Clinical & Experimental Ophthalmology

    Volume 36, Issue s1, June 2008, Pages: A459–A584,

    Version of Record online : 18 JUL 2008, DOI: 10.1111/j.1442-9071.2008.01760.x

  10. You have free access to this content
    One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization

    Acta Ophthalmologica

    Volume 92, Issue 8, December 2014, Pages: e615–e620, Ya-Hsin Kung, Tsung-Tien Wu and Ya-Hui Huang

    Version of Record online : 12 JUN 2014, DOI: 10.1111/aos.12457

  11. You have free access to this content
    Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate

    International Journal of Cancer

    Volume 129, Issue 8, 15 October 2011, Pages: 1979–1989, Sarah Jane Lunt, Simon Akerman, Sally A. Hill, Matthew Fisher, Victoria J. Wright, Constantino C. Reyes-Aldasoro, Gillian M. Tozer and Chryso Kanthou

    Version of Record online : 13 APR 2011, DOI: 10.1002/ijc.25848

  12. Combretastatin A4-phosphate and its potential in veterinary oncology: a review

    Veterinary and Comparative Oncology

    E. Abma, S. Daminet, P. Smets, Y. Ni and H. de Rooster

    Version of Record online : 18 MAY 2015, DOI: 10.1111/vco.12150

  13. SELECTIVE TARGETING OF THE TUMOUR VASCULATURE

    ANZ Journal of Surgery

    Volume 78, Issue 11, November 2008, Pages: 955–967, Lie S. Chan, Jurstine Daruwalla and Christopher Christophi

    Version of Record online : 21 OCT 2008, DOI: 10.1111/j.1445-2197.2008.04712.x

  14. Are the periodic changes of neurophysiological parameters during the pain-free interval in migraine related to abnormal orienting activity?

    Cephalalgia

    Volume 20, Issue 1, February 2000, Pages: 20–29, M Siniatchkin, W-d Gerber, P Kropp, T Voznesenskaya and Am Vein

    Version of Record online : 25 DEC 2001, DOI: 10.1046/j.1468-2982.2000.00002.x

  15. Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions

    Small

    Volume 11, Issue 31, August 19, 2015, Pages: 3755–3761, Wantong Song, Zhaohui Tang, Dawei Zhang, Haiyang Yu and Xuesi Chen

    Version of Record online : 28 APR 2015, DOI: 10.1002/smll.201500324

  16. Clinical Progress in Tumor Vasculature-disrupting Therapies

    Vascular-Targeted Therapies in Oncology

    Andrew M. Gaya, Gordon J. S. Rustin, Pages: 305–322, 2006

    Published Online : 31 MAY 2006, DOI: 10.1002/0470035439.ch17

  17. Copy number variation in the genomes of domestic animals

    Animal Genetics

    Volume 43, Issue 5, October 2012, Pages: 503–517, A. Clop, O. Vidal and M. Amills

    Version of Record online : 6 MAR 2012, DOI: 10.1111/j.1365-2052.2012.02317.x

  18. You have free access to this content
    Copy-number variation in the pathogenesis of autism spectrum disorder

    Psychiatry and Clinical Neurosciences

    Volume 68, Issue 2, February 2014, Pages: 85–95, Emiko Shishido, Branko Aleksic and Norio Ozaki

    Version of Record online : 29 DEC 2013, DOI: 10.1111/pcn.12128

  19. New treatments in age-related macular degeneration

    Clinical & Experimental Ophthalmology

    Volume 31, Issue 5, October 2003, Pages: 376–391, Claire Y Hooper and Robyn H Guymer

    Version of Record online : 26 SEP 2003, DOI: 10.1046/j.1442-9071.2003.00683.x

  20. Effects of the Tumor-Vasculature-Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels

    ChemMedChem

    Volume 9, Issue 4, April 2014, Pages: 847–854, Katharina Mahal, Dr. Marcus Resch, Prof. Dr. Ralf Ficner, Prof. Dr. Rainer Schobert, Dr. Bernhard Biersack and Dr. Thomas Mueller

    Version of Record online : 23 FEB 2014, DOI: 10.1002/cmdc.201300531